Tumor Lysis Syndrome
📧 Sign up to get email alerts when something new happens for Tumor Lysis Syndrome.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-03-12FDA Approved: ALLOPURINOL — Original Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved Unichem Pharmaceuticals (USA), Inc.'s original application for Allopurinol, a generic drug used to treat gout and hyperuric…
-
FDA approval · 2018-12-03FDA Approved: ALLOPURINOL — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Allopurinol filed by Rising Pharma Holdings, Inc.
-
FDA approval · 2017-09-14FDA Approved: ELITEK — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for ELITEK (rasburicase) submitted by Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2017-04-25Clinical Trial Update: Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
Completed trial evaluating rasburicase for chemotherapy- or malignancy-induced hyperuricemia in leukemia and lymphoma patients.
-
FDA approval · 2016-09-09FDA Approved: ALLOPURINOL SODIUM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Allopurinol Sodium (generic) from Hikma Pharmaceuticals USA Inc. under an ANDA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-07-28FDA Approved: ALLOPURINOL — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved an original (generic) application for allopurinol from Heritage Pharmaceuticals Inc. (d/b/a Avet Pharmaceuticals Inc.).
-
FDA approval · 2016-06-13FDA Approved: ELITEK — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for ELITEK (rasburicase) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2015-05-22FDA Approved: ELITEK — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approves a supplemental application for ELITEK (rasburicase) filed by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2015-05-13FDA Approved: ALOPRIM — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for ALOPRIM (allopurinol) submitted by Mylan Institutional LLC, resulting in updated labeling.
-
FDA approval · 2015-02-03FDA Approved: ELITEK — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approves a supplemental application for ELITEK (rasburicase) by Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2014-12-12Clinical Trial Update: Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia [Phase 3]
Phase 3 trial evaluating the safety and efficacy of rasburicase (TULY) for prevention and treatment of malignancy-associated hyperuricemia h…
-
CLINICAL_TRIALS trial_result · 2014-11-03Clinical Trial Update: Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies [Phase 3]
Phase 3 trial evaluating febuxostat to prevent tumor lysis syndrome in hematologic malignancies has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2013-08-01Clinical Trial Update: Rasburicase in Patients at Risk for Tumor Lysis Syndrome [Phase 2]
This clinical trial update reports results from a Phase 2 study of rasburicase in patients at risk for tumor lysis syndrome, which has compl…
-
CLINICAL_TRIALS trial_result · 2013-01-31Clinical Trial Update: Elitek (Rasburicase) Immuno-Monitoring Study
This clinical trial update reports that the immuno-monitoring study of Elitek (rasburicase) has been terminated.
-
CLINICAL_TRIALS trial_result · 2012-08-01Clinical Trial Update: Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS [Phase 1, Phase 2]
The study reports pharmacokinetic evaluation of rasburicase in patients with leukemia or lymphoma who are at high risk of tumor lysis syndro…
-
CLINICAL_TRIALS trial_result · 2009-12-31Clinical Trial Update: Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome [Phase 3]
Phase 3 trial comparing rasburicase to allopurinol in cancer patients at risk for hyperuricemia and tumor lysis syndrome has completed with …
-
FDA approval · 2009-10-16FDA Approved: ELITEK — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for ELITEK (rasburicase) submitted by Sanofi-Aventis U.S. LLC. The action confirms regulatory cleara…
-
CLINICAL_TRIALS trial_result · 2009-09-25Clinical Trial Update: Rasburicase in Tumor Lysis Syndrome [Phase 4]
Phase 4 trial update indicating completion of rasburicase studies for tumor lysis syndrome with associated hyperuricemia.
-
FDA approval · 2009-01-23FDA Approved: ALLOPURINOL — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for allopurinol from Actavis Pharma, updating the existing NDA.
-
CLINICAL_TRIALS trial_result · 2008-04-03Clinical Trial Update: Fasturtec TLS Treatment / Prophylysis [Phase 4]
Phase 4 trial of Fasturtec for tumor lysis syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2008-01-28Clinical Trial Update: Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome [Phase 4]
Phase 4 clinical trial evaluating rasburicase for treatment of hyperuricemia in children and adolescents with tumor lysis syndrome has compl…
-
FDA approval · 2007-09-10FDA Approved: ELITEK — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for ELITEK (rasburicase) submitted by Sanofi-Aventis U.S. LLC.